Publication date: Jun 24, 2025
In Japan, the prevalence of anxiety and depressive symptoms within the working population has risen. This has been accentuated by the economic repercussions of the COVID-19 pandemic and the social isolation resulting from remote work setups. Mobile health apps, particularly those incorporating cognitive behavioral therapy (CBT) features, have shown potential in addressing these symptoms. These self-guided CBT interventions hold promise in alleviating the heightened depressive and anxiety symptoms often observed among Japanese employees. Using a randomized controlled trial, we compared the efficacy of the “INTELLECT” app against a no-treatment control group in improving depressive symptoms and CBT skills among Japanese full-time employees at postintervention and 2-month follow-up. A total of 123 full-time Japanese employees were randomly allocated to either the intervention group (INTELLECT), where they engaged with self-help CBT features, or to a control group receiving no treatment. Intervention participants were required to engage with these features for at least 20 minutes per week over a span of 4 weeks. Weekly self-reported assessments were collected from all participants starting from baseline and continuing until the end of the 4-week intervention period. Subsequent assessments were conducted at 1-month and 2-month follow-up intervals. Linear mixed models were used to evaluate any effects of the self-guided intervention on depressive symptoms, as measured by the Patient Health Questionnaire-4, and cognitive behavioral skills, as measured by the Cognitive Behavioral Therapy Skills Scale. The app’s feasibility, usability, and acceptability ratings were also examined using the Implementation Outcome Scales for Digital Mental Health (iOSDMH). The final sample (n=73) consisted of 46 (63%) participants who were female, 23 (32%) participants who were male, and 4 (6%) participants who identified as other genders, with a mean age of 40. 4 (SD 10. 7) years. Significant time cD7 group interactions were found at postintervention and 2-month follow-up, with the intervention group (n=34) reporting significantly lower depressive symptoms than the control group (n=38) at postintervention (t364. 7426=-2. 243; P=. 03; Cohen d=-0. 57, 95% CI -1. 07 to -0. 06) and 2-month follow-up (t364. 6948=-3. 284; P
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Anxiety |
| disease | MESH | Depressive Symptoms |
| disease | MESH | COVID-19 pandemic |
| disease | IDO | intervention |
| drug | DRUGBANK | Coenzyme M |